Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in ocular mucous membrane pemphigoid
NCT05263505Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of baricitinib in ocular mucous membrane pemphigoid (OcMMP) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Treatment Response of Ocular Inflammation at 8 weeks. Started Feb 2022; status: terminated.
02
Drugs
baricitinib
03
Conditions
ocular mucous membrane pemphigoid (OcMMP)
Beyond the preview
Go deeper on NCT05263505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263505.